$XERS hits fresh 52-week highs on blowout Q3: $107M revenue, $0.06 EPS, and a $1B 2030 target!

钱云飞
10:40

What a monster quarter from $Xeris Pharmaceuticals Inc(XERS)$ Stock is pushing brand-new 52-week highs ($11.36+ pre-market) and it's completely deserved.

Look at the numbers they just reported: $107.2M in revenue (beat by $5.5M) and positive GAAP EPS of $0.06 (crushed the -$0.01 estimate). Recorlev is taking massive market share in Cushing's, gross margins are holding above 86%, and management just gave a long-term 2030 revenue target exceeding $1 Billion. Add in the fact that they retired $34M in convertible debt earlier and their Phase 3 for XP-8121 starts around year-end, and this isn't just a speculative biotech anymore—it's a profitable commercial compounder.

My execution plan:

  • Current: ~$10.41 – $10.75 (Surging to $11.36+)

  • Buy the retest: $10.15 – $10.40 (old ceiling becomes new floor)

  • Stop loss: Below $9.20

  • Targets: $12.50 short-term, $14.00+ on blue-sky expansion.

# Trade Feed: Who is your favorite trader?

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Report

Comment（7）

  • Top
  • Latest
  • Liping Tee
    ·11:44
    TOP
    i almost fell for the bear panic when $XERS tested the accumulation zone. still trying to understand how institutional accumulation works around the 50-day moving average, but owen's breakdown on 86% gross margins and setting a clear stop at below $9.20 helped clear up the confusion. thanks for the updates.
    Reply
    Report
  • Zhiayi Ong
    ·11:39
    TOP
    Just remember that even with 86% gross margins, no technical level at the 50-day moving average is a guarantee. Retail traders get burned when they treat $12.50 short-term, $14.00+ on blue-sky expans as a certainty and ignore the stop at below $9.20.
    Reply
    Report
  • Tsuen Seng Koh
    ·11:42
    TOP
    Every dip into the accumulation zone getting vacuumed right up tells you institutional buyers are quietly accumulating $XERS. I'm playing the gap fill first, and once we punch through the 200-day EMA resistance, the air pocket up to $12.50 short-term.
    Reply
    Report
  • Ay Ling Yong
    ·10:52
    The move is happening on declining volume. That's distribution, not accumulation. The implied volatility says the market is pricing a 7.0% swing, and nobody in this thread is. Is $XERS being traded as a tactical gap play or an accumulation hold? The advice changes completely. Happy to stay light on $XERS until we see how it reacts to the key moving averages and support levels.
    Reply
    Report
  • 方瀚珅.
    ·11:39
    If you plug 86% gross margins and core product demand scaling rapidly into a basic DCF with low net leverage, $XERS trading at a reasonable earnings multiple is massively mispriced. Reclaiming the 50-day moving average is just the market finally waking up to the cash flow math.
    Reply
    Report
  • Joon Han Woo
    ·11:46
    [Strong][Strong]
    Reply
    Report
  • Joon Han Woo
    ·11:46
    Yea
    Reply
    Report